Verve Therapeutics, Inc. (VERV) — Financial statements
Income statement, balance sheet, and cash flow for Verve Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 32↑175.0% | 12↑505.8% | 2 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 3↑154.3% | 1 | |
| Gross Profit | 32↑175.0% | 12↑505.8% | 2↑157.5% | -3↓154.3% | -1 | |
| Operating Expenses | ||||||
| R&D Expenses | 204↑10.5% | 185↑42.2% | 130↑90.7% | 68↑92.8% | 35 | |
| General & Administrative Expenses | 57↑13.4% | 50↑33.0% | 38↑99.0% | 19↑258.9% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 57↑13.4% | 50↑33.0% | 38↑99.0% | 19↑258.9% | 5 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 1↑104.5% | -33↓537.3% | -5 | |
| Operating Expenses | 261↑11.1% | 235↑40.1% | 168↑92.5% | 87↑114.3% | 41 | |
| Total Costs & Expenses | 261↑11.1% | 235↑40.1% | 168↑92.5% | 87↑114.3% | 41 | |
| Operating Results | ||||||
| Operating Income | -229↓2.5% | -223↓34.7% | -166↓90.3% | -87↓114.3% | -41 | |
| Depreciation & Amortization | 7↑23.8% | 5↓18.7% | 7↑98.7% | 3↑154.3% | 1 | |
| EBITDA | -222↓1.9% | -218↓33.6% | -163↓90.4% | -86↓117.6% | -39 | |
| EBIT | -229↓2.5% | -223↓34.7% | -166↓37.7% | -120↓196.1% | -41 | |
| Interest & Other Income | ||||||
| Net Interest Income | 29↑24.2% | 23↑237.4% | 7↑4735.9% | 0.14↓12.3% | 0.16 | |
| Interest Income | 29↑24.2% | 23↑237.4% | 7↑4735.9% | 0.14↓12.3% | 0.16 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↓100.0% | 33 | 0.00 | |
| Other Income / Expenses | 30↑29.9% | 23↑179.3% | 8↑125.1% | -33↓554.9% | -5 | |
| Income Before Tax | -198↑0.7% | -200↓27.0% | -157↓30.8% | -120↓163.2% | -46 | |
| Income Tax Expense | 0.35↑26.9% | 0.28↑418.9% | 0.05 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -199↑0.7% | -200↓27.1% | -157↓30.8% | -120↓163.2% | -46 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -199↑0.7% | -200↓27.1% | -157↓32.7% | -119↓160.5% | -46 | |
| Bottom-Line Net Income | -199↑0.7% | -200↓27.1% | -157↓30.8% | -120↓163.2% | -46 | |
| EPS (Basic) | -2.36↑24.4% | -3.12↓7.2% | -2.91↓18.8% | -2.45↓160.6% | -0.94 | |
| EPS (Diluted) | -2.35↑24.7% | -3.12↓7.2% | -2.91↓18.8% | -2.45↓160.6% | -0.94 | |
| Weighted Average Shares | 85↑32.0% | 64↑18.8% | 54↑11.4% | 49↑0.6% | 48 | |
| Weighted Average Diluted Shares | 85↑32.0% | 64↑18.8% | 54↑11.4% | 49↑0.6% | 48 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.